MX2016009226A - Combinaciones farmaceuticas. - Google Patents

Combinaciones farmaceuticas.

Info

Publication number
MX2016009226A
MX2016009226A MX2016009226A MX2016009226A MX2016009226A MX 2016009226 A MX2016009226 A MX 2016009226A MX 2016009226 A MX2016009226 A MX 2016009226A MX 2016009226 A MX2016009226 A MX 2016009226A MX 2016009226 A MX2016009226 A MX 2016009226A
Authority
MX
Mexico
Prior art keywords
combination
cancer
amide
prevention
subject
Prior art date
Application number
MX2016009226A
Other languages
English (en)
Spanish (es)
Inventor
Hirawat Samit
Massacesi Cristian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016009226A publication Critical patent/MX2016009226A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2016009226A 2014-01-15 2015-01-13 Combinaciones farmaceuticas. MX2016009226A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305057 2014-01-15
PCT/IB2015/050260 WO2015107461A1 (en) 2014-01-15 2015-01-13 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
MX2016009226A true MX2016009226A (es) 2016-10-05

Family

ID=50033443

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009226A MX2016009226A (es) 2014-01-15 2015-01-13 Combinaciones farmaceuticas.

Country Status (11)

Country Link
US (2) US20160331755A1 (enExample)
EP (1) EP3094340A1 (enExample)
JP (2) JP2017502989A (enExample)
KR (1) KR20160101027A (enExample)
CN (2) CN112535688A (enExample)
AU (2) AU2015207723A1 (enExample)
BR (1) BR112016012141A2 (enExample)
CA (1) CA2936783A1 (enExample)
MX (1) MX2016009226A (enExample)
RU (2) RU2020121929A (enExample)
WO (1) WO2015107461A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111757734A (zh) * 2017-12-28 2020-10-09 星座制药公司 通过组合疗法的ezh2抑制剂的药代动力学增强
CN115040523A (zh) * 2021-03-09 2022-09-13 上海翰森生物医药科技有限公司 Pi3k抑制剂联合雌激素受体拮抗剂在治疗肿瘤疾病中的用途
WO2023150267A1 (en) * 2022-02-03 2023-08-10 Maison Amori Oqvpo Llc Methods, compositions and uses for treating cancer by providing medications that induce targeted tumor cell mitosis before providing chemotherapy or radiation and kits therefor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
WO2006077425A1 (en) * 2005-01-21 2006-07-27 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CN101019828A (zh) * 2007-03-23 2007-08-22 济南帅华医药科技有限公司 一种含磷酸肌醇3－激酶抑制剂及激素类药物的抗癌组合物
EP2155753A1 (en) * 2007-05-09 2010-02-24 Novartis Ag Substituted imidazopyridazines as pi3k lipid kinase inhibitors
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
EP2558463A1 (en) * 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2012009649A1 (en) * 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
CN103764144B (zh) * 2011-08-31 2016-07-20 诺华股份有限公司 Pi3k抑制剂与mek抑制剂的协同组合
CA2867700A1 (en) * 2012-03-23 2013-09-26 Memorial Sloan-Kettering Cancer Center Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition
WO2015081127A2 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders

Also Published As

Publication number Publication date
CN105916515A (zh) 2016-08-31
JP2020023497A (ja) 2020-02-13
EP3094340A1 (en) 2016-11-23
RU2016133285A (ru) 2018-02-20
CA2936783A1 (en) 2015-07-23
WO2015107461A1 (en) 2015-07-23
AU2017245302A1 (en) 2017-11-02
JP2017502989A (ja) 2017-01-26
US20160331755A1 (en) 2016-11-17
KR20160101027A (ko) 2016-08-24
RU2016133285A3 (enExample) 2018-08-28
CN112535688A (zh) 2021-03-23
US20170304311A1 (en) 2017-10-26
AU2017245302B2 (en) 2019-04-04
RU2020121929A (ru) 2020-07-13
AU2015207723A1 (en) 2016-06-09
BR112016012141A2 (pt) 2017-08-08
US10085996B2 (en) 2018-10-02

Similar Documents

Publication Publication Date Title
MX2015017629A (es) Combinaciones farmaceuticas.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
MX383866B (es) Inhibidores de ezh2 para tratar linfomas.
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
IL314347A (en) Combined treatment of lasmiditan and a CGRP antagonist for use in the treatment of migraine
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
SG10201811185YA (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
IN2015DN00376A (enExample)
HRP20220718T1 (hr) Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
WO2007058990A3 (en) Therapy using cytokine inhibitors
MX382162B (es) Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.
MX2015000746A (es) Terapia de combinacion de inhibidores para el receptor del factor de crecimiento insulinico tipo 1 (igf1r) y fosfatidilinositol 3-cinasa (pi3k).
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
MX2015017058A (es) Combinaciones farmaceuticas de un inhibidor de pi3k y un agente de desestabilizacion de microtubulos.
MX368734B (es) (s)-pirlindol o sus sales farmaceuticamente aceptables para uso en medicina.
WO2015035410A8 (en) Cancer therapy
MX2016010482A (es) Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer.
HK1199832A1 (en) Combination therapy using ribavirin as eif4e inhibitor
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
BR112016012141A2 (pt) "combinações farmacêuticas, uso das mesmas, e embalagem comercial"
IL284980B1 (en) Heteroaryl-azacyclic-oxo-amide compound, pharmaceutical preparation and pharmaceutical preparation for use in the treatment